SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
September 2025 — Vol. 2, No. 9
Page 4 of 4 of this archive, newest first.
Also filed — page 4
the rolling newsroom, September 2025Canada declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
STEP 4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Norway caps tirzepatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What changed at MKM in September, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
India pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Poland caps tirzepatide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What the new Australia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Xi'an: 15 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Homopeptide declines, for the 24th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
New Zealand health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to Japan after 5 consecutive customs detentions
The route did not close because of a rule about peptides.
What changed at Homopeptide in September, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 29-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.